PAYNE JOHN BERNARD

ZIVO CEO John Bernard Payne buys 11,709 shares at $8.54 (2026-01-26); holdings +148.0%; cluster activity detected.

CEO John Bernard Payne purchased 11,709 shares at $8.54 on 2026-01-26, increasing his holdings by 148.0% from 7,909 to 19,618 shares, with a total transaction value of $99,994.86. This buy coincides with 3 other insiders buying within the past 14 days, indicating a cluster buy pattern. Zivo Bioscience is currently unprofitable (net income of $-1,033,056.00 for the latest full fiscal year) but shows strong annual revenue growth of +468.6%, though quarterly revenue remains modest at $65,625.00. The stock has declined 58.1% from its 52-week high of $21.49 and is trading at $9.00, down 35.7% over 90 days, yet the insider's prior purchase at this ticker in 2024 delivered positive 90-day returns, consistent with his 100% win rate across his cross-ticker track record.

CEO John Payne buys 6,343 shares at $15.76, increasing stake 405% to 7,909 shares; stock now at $20.50

CEO John Bernard Payne purchased 6,343 shares at $15.76 on 2024-10-16, tripling his position from 1,566 to 7,909 shares and deploying $99,965.68 in the transaction. The stock has since risen to $20.50, up 57.7% over the past 30 days and 147.9% over the past 90 days. Despite the strong recent price momentum, ZIVO remains unprofitable with $-8,236,368.00 net income in its most recent full fiscal year and $0.00 revenue in the latest quarter, raising a material disconnect between valuation and fundamentals. The CEO's significant capital commitment during a period of operational losses and zero quarterly revenue warrants examination of whether this reflects conviction in a turnaround strategy or carries other implications for ongoing business performance.